Spagnuolo Vincenzo Professore AssociatoMedicineMEDS-10/B

Educational training: Degree in Medicine and Surgery (2006) and post-degree specialization in Infectious Diseases (2011) both awarded by University Vita-Salute San Raffaele, Milan.

Past employments and appointments: Infectious Diseases Consultant, Department of Infectious Diseases, Ospedale San Raffaele, Milan

Research Fellow UniSR, 2013-2015.

Fellowship recipient, Italian Society for Tropical and Infectious Diseases (SIMIT), 2015-2016.

Actual position: From October 2016 (to present): Researcher (MED/17), Vita-Salute San Raffaele University, Milan, Department of Infectious Diseases

Areas of interest: HIV, antiretroviral therapy, metabolic complications of HIV infection, sexually transmitted diseases, viral hepatitis, antimicrobial therapy

Publications: Author of 45 scientific articles published in peer-review journals and 30 abstracts presented in different international congresses.

Orcid number: 0000-0002-9656-7217

SELECTION OF PUBLICATIONS

– Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients. Spagnuolo V, Galli L, Poli A, Salpietro S, Gianotti N, Piatti P, Cossarini F, Vinci C, Carini E, Lazzarin A, Castagna A BMC Infect Dis. 2017; 17:43. doi: 10.1186/s12879-016-2099-5.

– Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment. Spagnuolo V, Cocorullo D, Galli L, Bigoloni A, Galli A, Rubinacci A, Mignogna G, Carbone A, Lazzarin A, Castagna A. J Antimicrob Chemother. 2013 Jun 27.

– Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: a matched cohort study. Spagnuolo V, Travi G, Galli L, Cossarini F, Guffanti M, Gianotti N, Salpietro S, Lazzarin A, Castagna A. Cancer. 2013;119:2710-9.

– Ten-year survival among HIV-infected subjects with AIDS- or non-AIDS-defining malignancies. Spagnuolo V, Galli L, Salpietro S, Gianotti N, Guffanti M, Cossarini F, Bigoloni A, Cinque P, Bossolasco S, Travi G, Fumagalli L, Lazzarin A, Castagna A. Int J Cancer 2012; Jul 27. doi: 10.1002/ijc.26332

– Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1 infected multidrug-resistance patients. Spagnuolo V, Gianotti N, Seminari E, Galli L, Fusetti G, Salpietro S, Lazzarin A, Castagna A. J Acquir Immune Defic Synd 2009; 50: 192-5

-Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies. Cancer Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord. Clin Infect Dis. 2016; 63:1373-1379.

-Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study. Wang Q, De Luca A, Smith C, Zangerle R, Sambatakou H, Bonnet F, Smit C, Schommers P, Thornton A, Berenguer J, Peters L, Spagnuolo V, Ammassari A, Antinori A, Quiros-Roldan E, Mussini C, Miro JM, Konopnicki D, Fehr J, Campbell MA, Termote M, Bucher HC; Hepatitis Coinfection and Non Hodgkin Lymphoma project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Ann Intern Med. 2017;166: 9-17. doi: 10.7326/M16-0240

– Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels. Spagnuolo V, Gentilini G, De Bona A, Galli L, Uberti-Foppa C, Soldarini A, Dorigatti F, Seminari E. New Microbiol 2007; 30: 279-82.

– Use of statins and risk of AIDS-defining and non-AIDS defining malignancies among HIV-1 infected patients on antiretroviral therapy. Galli L, Spagnuolo V, Poli A, Salpietro S, Gianotti N, Cossarini F, Carbone A, Nozza S, Bossolasco S, Bigoloni A, Lazzarin A, Castagna A. AIDS. 2014

– Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: the MODAt trial. Castagna A, Spagnuolo V, Galli L, Vinci C, Nozza S, Carini E, D’Arminio Monforte A, Montella F, Antinori A, Di Biagio A, Rusconi S, Lazzarin A .AIDS. 2014; 28:2269-79

– Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy. Gianotti N, Poli A, Nozza S, Spagnuolo V, Tambussi G, Bossolasco S, Cinque P, Maillard M, Cernuschi M, Galli L, Lazzarin A, Castagna A. J Int AIDS Soc. 2015 Jul 30;18:20037. doi: 10.7448/IAS.18.1.20037.

– HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients. Gianotti N, Canducci F, Galli L, Cossarini F, Salpietro S, Poli A, Nozza S, Spagnuolo V, Clementi M, Sampaolo M, Ceresola ER, Racca S, Lazzarin A, Castagna A. Clin Microbiol Infect. 2015;21:103.e7-103.e10

– Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up. Gianotti N, Galli L, Salpietro S, Cernuschi M, Bossolasco S, Maillard M, Spagnuolo V, Canducci F, Clementi M, Lazzarin A, Castagna A. Clin Microbiol Infect. 2013 May 15.doi: 10.1111/1469-0691.12266.

– Glucose tolerance in HIV-1 treated patients who switched from boosted-protease inhibitors to etravirine. Carbone A, Bigoloni A, Galli L, Spagnuolo V, Gianotti N, Lazzarin A, Castagna A. AIDS 2013; 27: 2661-3.

– Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens. Bigoloni A, Gianotti N, Spagnuolo V, Galli L, Nozza S, Cossarini F, Salpietro S, Carini E, Piatti P, Vinci C, Lazzarin A, Castagna A. AIDS. 2012;26:1837-40.

– Monotherapy with atazanavir as a simplification strategy: results from an observational study. Cossarini F, Salpietro S, Galli L, Gianotti N, Nozza S, Spagnuolo V, Hasson H, Bossolasco S, Lazzarin A, Tambussi G, Castagna A . J Acquir Immune Defic Syndr. 2012;60:e101-3.

– Levels of soluble endothelial protein C receptor are associated with CD4+ changes in Maraviroc-treated HIV-infected patients. Nozza S, Pogliaghi M, Chiappetta S, Spagnuolo V, Fontana G, Razzari C, Tambussi G, Faioni EM. PLoS One. 2012;7:e37032.

– Immune recovery and T cell subset analysis during effective treatment with maraviroc. Cossarini F, Galli A, Galli L, Bigoloni A, Salpietro S, Vinci C, Della Torre L, Gianotti N, Spagnuolo V, Lazzarin A, Castagna A, Nozza S .J Antimicrob Chemother. 2012;67:2474-8.

– Mortality of HIV-infected patients with or without cancer: comparison with the general population in Italy. Galli L, Spagnuolo V, Salpietro S, Gianotti N, Cossarini F, Lazzarin A, Castagna A. Antiviral Therapy 2011. doi: 10.3851/IMP1984

– Residual viremia does not influence 1 year virologic rebound in HIV-infected patients with HIV-RNA persistently below 50 copies/ml. Gianotti N, Galli L, Racca S, Salpietro S, Spagnuolo V, Barda B, Canducci F, Clementi M, Lazzarin A, Castagna A. J Antimicrob Chemoter 2012 Jan; 67 (1): 213-7

– Cross-resistance profile of the novel integrase inhibitor dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. Canducci F, Ceresola ER, Boeri E, Spagnuolo V, Cossarini F, Castagna A, Lazzarin A, Clementi M. J Infect Dis 2011 Dec; 204 (11): 1811-5

– Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV infection. Castagna A, Cossarini F, Spagnuolo V, Gianotti N, Galli L. J Acquir Immune Defic Synd 2011 Jan; 56 (1): e34-5

– Integrase and fusion inhibitors transmitted drug resistance in naive patients with recent diagnosis of HIV-infection. Cossarini F, Boeri E, Canducci F, Salpietro S, Bigoloni A, Galli L, Spagnuolo V, Castagna A, Clementi M, Gianotti N. J Acquir Immune Defic Synd 2011 Feb; 56 (2)e: 51-4

– Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption. Canducci F, Barda B, Ceresola E; Spagnuolo V, Sampaolo M, Boeri E, Nozza S, Cossarini F, Galli A, Gianotti N, Castagna A, Lazzarin A, Clementi M. Clin Microbiol Infect 2011; 17: 928-34. PMID: 20854427

– Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. Canducci F, Marinozzi MC, Sampaolo M, Boeri E, Spagnuolo V, Gianotti N, Castagna A, Paolucci S, Baldanti F, Lazzarin A, Clementi M. J Antimicrob Chemother 2010 Mar; 65 (3): 425-33